Psoriasis treatment in Kochi,
topical to biologic ladder, IADVL consensus.

There is no single 'best', psoriasis severity decides the protocol. Mild plaque psoriasis (PASI<10) responds to topical corticosteroid + vitamin D3 analogue (calcipotriol) + emollients. Moderate (PASI 10-20) typically adds NB-UVB phototherapy 2-3×/week × 24-36 sessions, or oral methotrexate 7.5-25 mg weekly with monthly LFT monitoring. Severe (PASI>20) or treatment-failed cases escalate to cyclosporine, oral acitretin, or biologics (secukinumab, itolizumab, adalimumab biosimilar). DermaVue Kochi follows the IADVL India guidelines published in IJDVL, a graded protocol led by Dr. Minu Liz Mathew (MD DVL).

No, psoriasis is a chronic immune-mediated condition with no permanent cure. The goal is long-term remission and disease control. With the IADVL graded protocol, the majority of moderate-severe psoriasis patients achieve PASI-75 (75% reduction) or PASI-90 within 12-24 weeks of starting appropriate therapy. Biologic-treated patients commonly maintain PASI-90 for years on continued therapy. Stopping therapy typically leads to relapse within weeks to months, long-term maintenance is part of the disease model, not a treatment failure.

Yes · DermaVue Kochi prescribes the biologics currently available in India: secukinumab (IL-17A inhibitor, 300 mg SC at weeks 0, 1, 2, 3 then every 4 weeks); itolizumab (Indian-developed anti-CD6 monoclonal antibody, 1.6 mg/kg IV); adalimumab biosimilar (TNF-α blocker, 40 mg SC every 2 weeks, originator not currently available in India). Pre-biologic screen (TB, Hep B/C, HIV, chest X-ray) is mandatory. The dominant access barrier in Indian practice is cost: 88% of Indian dermatologists report cost as the main constraint on biologic prescribing per an IADVL survey.

Secukinumab full-year programme (loading 4 doses + 12 maintenance doses) is approximately ₹3-5 lakh depending on brand. Adalimumab biosimilar (Indian-manufactured) is approximately ₹1.5-2.5 lakh per year, a meaningful cost reduction versus the originator (not available in India). Itolizumab 24-week induction programme is approximately ₹1.5-3 lakh. DermaVue Kochi provides transparent written annual cost projection before commitment, biologic therapy is a long-term commitment and cost transparency is part of informed consent.

Yes, PM2.5 exposure exacerbates psoriasis through oxidative-stress-mediated keratinocyte activation, confirmed by a 2025 PMC systematic review. Kochi's PM2.5 sits at approximately 3× the WHO annual safe limit (CPCB Vyttila monitoring station peak 51 µg/m³). Outdoor commuters and Cochin Shipyard / industrial-corridor workers face higher flare frequency. DermaVue's protocol includes PM2.5 mask recommendation for outdoor commute, smoking cessation counselling, and acknowledgment of pollution as a disease-modifying factor.

Some patients combine ayurvedic regimens with conventional therapy. The published evidence base for ayurvedic monotherapy is limited and uncontrolled · DermaVue's position is that for mild psoriasis, supplementary ayurvedic regimens with daily emollients and lifestyle changes are reasonable as adjunct (not substitute), but for moderate-severe psoriasis the IADVL conventional protocol is the evidence-supported foundation. Some 'herbal' creams sold for psoriasis contain undeclared topical steroids, particularly clobetasol, leading to long-term skin atrophy and steroid rebound when discontinued. Patch testing or unbiased product sourcing helps avoid this.

Both are conventional first-line systemics for moderate-severe psoriasis but differ in onset, duration of use, and side effect profile. Methotrexate (7.5-25 mg weekly + folate supplementation) is slower acting (clinical response over 8-16 weeks) but suitable for long-term maintenance with monthly LFT monitoring. Cyclosporine (3-5 mg/kg/day) is faster acting (response in 4-8 weeks) but typically limited to 12-24 weeks of continuous use due to renal toxicity risk; BP + creatinine monitoring monthly. DermaVue selects per patient profile, comorbidity, age, response speed required.

Scalp psoriasis is a plaque-pattern inflammatory condition with thick silvery scales on well-demarcated red plaques; dandruff (seborrhoeic dermatitis) shows diffuse fine scaling on diffuse erythema without sharp plaque demarcation. Both can itch, clinically and histologically they're distinct. DermaVue uses dermoscopy + careful exam to distinguish; protocols differ (psoriasis: topical steroid + calcipotriol + tar; SD: anti-Malassezia ketoconazole + zinc pyrithione).

The published evidence base for dietary intervention in psoriasis is modest. Mediterranean-style diet (high vegetable, olive oil, fish, low refined carbohydrate, low red meat) shows mild PASI improvement in trial cohorts. Weight loss in overweight psoriasis patients (BMI > 25 per Indian threshold) meaningfully improves biologic response and reduces disease severity · DermaVue's SuperHuman metabolic programme (Dr. Rejeesh Menon, MD Internal Medicine) is sometimes co-prescribed for psoriasis patients with metabolic comorbidity. Smoking and alcohol independently worsen psoriasis; cessation is part of the protocol.

Yes, nail psoriasis affects 40-50% of plaque psoriasis patients. Pitting (small surface depressions), oil-spot discolouration, onycholysis (nail separation from bed), and subungual hyperkeratosis are the typical findings. Nail psoriasis is associated with higher risk of psoriatic arthritis development. Treatment is harder than skin (nail bed is hard to penetrate topically): topical corticosteroid + vitamin D under occlusion, intralesional steroid injection for severe disease, or systemic / biologic therapy if skin involvement is also moderate-severe.